Italia markets close in 2 hours 3 minutes

FTSE MIB
34.611,73
+151,21(+0,44%)
Dow Jones
39.671,04
-201,95(-0,51%)
Nasdaq
16.801,54
-31,08(-0,18%)
Nikkei 225
39.103,22
+486,12(+1,26%)
Petrolio
78,48
+0,91(+1,17%)
Bitcoin EUR
63.834,59
-430,51(-0,67%)

Neurocrine Biosciences, Inc. (0K6R.L)

LSE - LSE Prezzo differito. Valuta in USD.

Aggiungi a watchlist

140,53

-0,39

(-0,28%)

In data: 07:14PM BST. Mercato aperto.

Caricamento grafico interattivo in corso...

GlobeNewswire
Sosei Heptares’ partner Neurocrine Biosciences Initiates Phase 1 Clinical Study Evaluating Effects of NBI-1117570 in Healthy Adults
NBI-1117570 is an investigational, oral, muscarinic M1/M4 selective dual agonist discovered by Sosei Heptares that may have the potential to treat neurological and neuropsychiatric conditionsNBI-1117570 is the second compound to advance into clinical development from a portfolio of selective muscarinic receptor agonists licensed by Sosei Heptares to Neurocrine following NBI-1117568, an oral, selective muscarinic M4 receptor agonist, which is in Phase 2 clinical trials as an investigational treat